Price
Target price
-
-
-
-
-
?3.70
WKN: A2AJW8 / Symbol: ADVM / Name: Adverum Bio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Adverum Biotechnologies Inc. Stock
Currently there is a rather positive sentiment for Adverum Biotechnologies Inc. with 4 Buy predictions and 1 Sell predictions.
Based on the current price of 1.38 € the target price of 3 € shows a potential of 117.39% for Adverum Biotechnologies Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Adverum Biotechnologies Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Adverum Biotechnologies Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Adverum Biotechnologies Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 0.100% | -7.414% | -16.973% | 36.533% | 6.298% | -15.255% | - |
| Salarius Pharmaceuticals Inc. | 0.930% | 6.468% | -31.520% | -69.209% | -22.883% | -98.226% | -99.994% |
| Evolus Inc | -2.630% | -5.882% | -12.500% | 43.590% | 19.786% | 18.519% | - |
Comments
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for ADVM provided by MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ADVM provided by MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at Mizuho. They set a "buy" rating and a $2.00 price target on the stock.
Show more
Ratings data for ADVM provided by MarketBeat